Chong Kun Dang Pharmaceutical (XKRX:185750) Short-Term Debt & Capital Lease Obligation : ₩175,769 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Chong Kun Dang Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩175,769 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Chong Kun Dang Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩41,213 Mil.

Chong Kun Dang Pharmaceutical Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Short-Term Debt & Capital Lease Obligation Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

92,212.97

78,632.09

102,091.45

124,445.50

184,767.37

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															137,630.03	107,556.60	186,026.74	184,767.37	175,768.62

Chong Kun Dang Pharmaceutical Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Chong Kun Dang Pharmaceutical Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Short-Term Debt & Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines